Index

Abdominal distension in lung elastance 345, 346
Abdominal paradox 27
N-Acetylcysteine 79–80, 81, 357, 358
Acinetobacter baumanii, SDD for 260
Acute hypoxaemic respiratory failure defined 115
Acute lung injury (ALI)
  blast injuries 212
  hypoxaemia, PEEP management of 124–125
  infants/children 300–301
  liquid ventilation 228
  patient assessment 118, 115–119, 120, 197
  recruitment manoeuvres 131, 219
  ventilation management
    HFV 149–150
    IRV 125–126
    modes 215–216
    overview 214
    principles 214–215
Acute necrotizing myopathy 205, 205, 356
Acute quadriplegic myopathy syndrome (AQMS) 177
Acute renal failure 156
Acute respiratory distress syndrome (ARDS)
  APRV therapy 110–112
  blast injuries 212
  causes 214
  CT assessment 265
  delirium in 169
  dornase alfa 79–80
  drugs for 81, 137
  high tidal volume ventilation in 153–154
  hypoxaemia, PEEP management of 124–125
  inertia/friction issues 347, 333–347
  lung contusions 219
  nitric oxide as therapy 139
  oxygen toxicity 270
  patient assessment 118, 115–119, 120
  recruitment manoeuvres 118–119, 131, 219
  trials (*See* ARDS net trials)
  ventilation management
    HFOV 127–131, 305–306
    IRV 125–126
    liquid 228
    modes 215–216
    overview 214
    principles 214–215, 216
Acute respiratory failure (ARF)
  clinical presentation 29
  mechanisms of 24
  NIV 43, 49–50 (*See also* Non-invasive ventilation (NIV))
  overview 24, 22–24, 25, 142
Adaptive support ventilation® 113, 361
Adrenaline 81
Adrenergic receptor antagonists 349, 348–349, 350
Adverse effects/complications
  analgesia 276–280
  artificial airway management 58, 62–63, 72–73
  aspiration 242–243, 247, 266
  aspiration pneumonitis 242–243, 245
  barotrauma (*See* Barotrauma)
  benzodiazepines 165, 276–280
  bronchopleural fistula 252–253, 255
  cardiovascular effects 271, 272, 277
  cervical spine damage 245, 243–245
  dental/soft tissue/laryngeal 243
  dexmedetomidine 166
  endotracheal intubation 58, 72–73, 240, 239–240, 242, 246
  extubation, un-planned 249–250
  face/lips/oropharynx 245, 246
  fentanyl 276–280
  gastrointestinal system 274–276
  hypotension/hypoxia 239–242
  incidence data 240
  laryngeal injuries 248, 247–248
  left ventricular performance 273
  lorazepam 165
  lung injury, ventilator-associated (*See* Lung injury, ventilator-associated)
  maxillary sinusitis/middle ear effusions 246–247
  midazolam 165
  nasopharyngeal airways 243–245, 246–247
  nasotracheal intubation 315
  neurological function 277, 276–277, 278, 280
  NMBAs 171, 176–177, 276–280
  NSAIDs 181
  opioid agonists 180
  opioids 276–280
  overview 21, 239, 241
  oxygen toxicity 270, 269–270
  paralysis 176–177
  PEEP 125, 126, 198
  perforations 243
  pharyngo-laryngeal dysfunction 247
  pneumothorax 241–242
  propofol 165–166, 276–280
  pulmonary vascular resistance 272–273
  reduction 245, 246
  regurgitation 242–243, 247, 266
  remifentanil 276–280
  right ventricular performance 272, 274
  sedation 165–166, 245, 276–280
  sleep 276, 277, 278, 279, 349, 348–349, 350, 384
  sufentanil 276–280
  swallowing dysfunction 247, 247
  tracheal injuries 243, 249, 248–249
  tracheostomy (*See under* Tracheostomy)
  trauma 43

Adverse effects/complications (*cont.*)
VAP (*See* Ventilator-associated pneumonia (VAP))
venous return 271–272, 273
VIDD (*See* Ventilator-induced diaphragmatic damage (VIDD))
withdrawals 278, 276–278, 280
Aerial transport issues in low P_{O_2} 13
Aeromedical transportation issues 290, 294, 293–294, 295
Aerosol drug delivery
factors affecting 85
metered dose inhalers 83, 84
method selection 83
nebulizers (*See* Nebulizers)
overview 81, 80–81, 82
AIDS 359–360
Airway collapse, risk factors 1–4
Airway development, upper 297
Airway obstruction
children 298, 306
Heliox 232
hypotension/circulatory collapse 205–206
management 311, 363, 362–363, 364
pathophysiology 197, 196–197, 198, 363
pneumothorax 206–207
problems associated with 196, 203
tracheostomy 78, 311, 312, 319
tracheostomy/tracheobronchial suctioning 78
Airway patency 363, 362–363, 364
Airway pressure, increasing 122, 123
Airway pressure release ventilation (APRV)
applications of 122, 123
described 110–112, 113
inspiratory time prolongation by 126–127
Airway protection 364, 365
Airway resistance, in infants/children 298–299
Alfentanyl 62–63
ALI. *See* Acute lung injury (ALI)
Almitrine bismesylate, for $\dot{V}/\dot{Q}$ mismatch 137
Alternative recruitment hypothesis 254
Alveolar-arterial difference calculation 116–119
Alveolar dead space defined 143–145
Alveolar shunts in low P_{O_2} 14–15
Alveoli
development of 296–297
diffuse haemorrhage 137, 137, 139
functional anatomy 3, 4
minute volume increase/pH 350, 350, 351
oxygenation of, surface area in 122, 121–122
pressure mechanics 5, 4–5, 9–11, 268
recruitment
in lung elastance 346, 345–346
in muscle contraction 353
surfactant dysfunction 267, 265–267
surfactant in 6, 4–6, 9, 267
$\dot{V}/\dot{Q}$ ratios 15, 120–121, 136, 133–136, 139
ventilation inequality in low P_{O_2} 15–16, 17
wall stress, inspiration and 266
Amikacin 81, 256–257
Aminoglycosides 256–257
Aminophylline 201, 360
Aminosteroid NMBA agents 174, 175–176
Anaesthesia, history of
pneumothorax 392–394
sealed airway 390–392
Anaesthetic ventilator modes 88–90
Analgesia
acetaminophen 180
adverse effects 276–280
as delirium risk factor 168–169
monitoring 178
NSAIDs 180, 181
opioid agonists 168–169, 179, 178–179, 180
overview 178
Anatomical dead space defined 143–145
Androgens 359–360
Antadir 376–377
Anti-cholinergic drugs
asthma/COPD 200
mucus production, decreasing 80
primary post-ventilation apnoea 334–336
Anti-depressants 348–350
Anti-fibrinolytics 137
Anti-pyretics 148
Antibiotic resistance 261
Anticholinesterases 334–336
Antimuscarinics 81
Antipsychotics 170–171
Anxiety 349, 348–349, 350
APACHE II model, hyperoxia 270, 271
Apnoea
in infants/children 299–300
primary post-ventilation 336, 334–336
secondary 340, 339–340
ventilation 106
Aprotinin 137
APRV. *See* Airway pressure release ventilation (APRV)
AQMS (acute quadriplegic myopathy syndrome) 177
ARDS. *See* Acute respiratory distress syndrome (ARDS)
ARDSnet trials
lung injury, ventilator-associated 263–265
NMBA usage 171
PEEP 124, 125, 146, 216, 267–269
permissive hypercapnia 153, 154, 155
ventilation modes 215
ARF. *See* Acute respiratory failure (ARF)
Arginine 190
Aripiprazole 170–171
Arterial blood gas measurement 29–30
Arterial oxygen content, calculating 119
Artificial airway management, lower
active HMEFs 74
aerosol drug delivery 80–83
complications 72–73 (*See also* Adverse effects/complications)
HMEFs 74, 75
hot water humidifiers 74–75
humidification 74
mucoactive agents 78–80
overview 72–73
tracheobronchial suctioning 75–78
tube exchange 83
tubing, monitoring 83–85
Artificial airway management, upper
breathing system care
cuff deflation 71
cuff inflators, manual 70
cuff pressure control 71, 69–71
oral hygiene 72
securing, of tube 69, 67–69
sub-glottic secretion drainage 72, 71–72, 262
Combitube 56, 57
complications 58, 62–63, 72–73 (*See also* Adverse effects/complications)
cricoid pressure application technique 63
drugs/venous access 62–63
endotracheal tubes (*See* Endotracheal intubation)
equipment 59, 60–61
indications 58
LMAs 56, 57
monitoring 59
nasopharyngeal airways 55, 56
oropharyngeal airways (*See* Oropharyngeal airways)
overview 54, 55
oxygenation 58–59, 60, 61, 62
placement 57–58

suction apparatus 61–62
tilting bed/trolley 61
tube cutting technique 66
ventilator 63
Artificial lungs 227–228
Aspiration
as adverse effect 242–243, 247
foreign body, in infants/children 297
gastric residual volumes and 188–189
lung transplantation 224–225
meconium aspiration syndrome 81, 303–304
pulmonary, risk factors 242
tidal volume and 266
transportation issues 287
VAP transmission via 257, 258–261
Aspiration pneumonitis 242–243, 245
Assessment, of need
arterial blood gases 29–30
availability principle 22
clinical 23, 29, 25–29, 30, 144
diaphragmatic function 27
hypercapnia 22–25, 26
lung volume measurement 27
maximal inspiratory pressure 27
neurological disorders 30
overview 21
patient categories 22–25
pulse oximetry 28, 27–28, 29
quality/length of life principle 22
rate/tidal volume 26–27
reversibility principle 21–22
support, goals of 25
thoraco-abdominal motion 27
Assist pressure control mode 108, 109
Assist volume control mode 108, 109
Asthma
acute necrotizing myopathy 205, 205
airflow obstruction, pathophysiology 196–198
circulatory collapse 206, 205–206
clinical presentation 198, 199
management
aminophylline 201
bronchodilators 149
cysteinyl leukotriene modifiers 201
dornase alfa 79–80
follow-up 207
glucocorticoids 80
Heliox 231, 234
lactic acidosis 200–201
magnesium sulphate 201
mechanical ventilation 203, 202–203, 204
NIV 49, 201–202
PEEP 204
sodium cromoglycate/nedocromil sodium 201
standard therapy 199–200
metabolic acidosis/hypercapnia in 155–156
muscle fatigue and 24–25
pneumothorax 206–207
Astrup, Poul 397–401
ATC (automatic tube compensation) 114
Atelectasis 23–24
Atracurium
AQMS and 177
overview 174–175
properties 175
study data 174
Auer, J. 393
Augmented diffusion 305–306
Automatic tube compensation (ATC) 114
Automode® 113
Availability principle 22

β-blockers 348–350
Barometric pressure issues in low P_{O_2} 13
Barotrauma
blast injuries 213, 216–217
causes 253
clinical presentation 250, 251
permissive hypercapnia and 154
pneumothorax and 250–253
risk factors 101, 126
RMs and 131
Basiliximab 224
Beecher, Henry 393–394
Beneficial studies, ventilation modes 215–216
Benzodiazepines. *See also specific agents*
adverse effects 165, 276–280
artificial airway management 62–63
delirium treatment 170, 348–350
history of 310
primary post-ventilation apnoea 336, 334–336
as sedatives, overview 163–164, 178
withdrawals 278
Benzylisoquinolinium NMBA agents 174–175
Bert, Paul 269
Beta 2 adrenergic agonists
asthma/COPD 137, 199–200, 202
bronchospasm 81
gastroesophageal reflux 274–275
in hypercapnia management 149
lactic acidosis 200–201
Beta-lactams 256–257
Bicarbonate retention 156
BiPAP (bi-level pressure support) 378
Bispectral index (BIS) monitor 162
Bjørneboe, Mogens 397–401
Blast injuries
barotrauma 213, 216–217
bronchopleural fistula 213
classification 213
clinical presentation 212, 213–214
diagnosis 211–212
explosions, physics of 210
incidence 212–213
outcomes 217
primary described 210–211, 213
quaternary described 211
radiographic findings 213
secondary described 211
sucking chest wounds 213
systemic effects of 217
tertiary described 211
treatment
ECMO 217
fluid administration 217
overview 214
PIP/permissive hypercapnia 216–217
ventilatory strategy, long-term 214
Blast waves 210
Blast wind 210
Blast zone anatomy 211
Blease, John 395, 394–395
Blease Pulmoflator 394–395
Blood, gas exchange 9–11
Blood perfusion in low P_{O_2} 16–17, 18
Bohr effect 146–147
Bohr equation 145
Both, Edward 396–397
Both Respirator 396–397
Bott COPD/NIV study data 45
Brauer, Ludolph 393
Breathing
expiratory cycling 90–91
features of 89, 88–89, 90, 95
inspiratory cycling described 90
muscle contraction in 351–352
periodic 299, 299, 300, 340
respiratory cycle 89, 88–89, 90
spontaneous 90, 95, 105, 107
triggered 90, 94–95, 105, 107
Breathing system care
cuff deflation 71
cuff inflators, manual 70
electronic cuff pressure controller 71, 70–71
foam-filled HVLP cuff 70
Lanz inflation balloon 70, 71
oral hygiene 72
securing, of tube 69, 67–69
sub-glottic secretion drainage 72, 71–72, 262
Brochard COPD/NIV study data 45

Bronchi/bronchioles, functional anatomy 3, 3, 4
Bronchiolitis 304–305
Bronchodilator therapy 149
Bronchopleural fistula 252–253, 255
Bronchospasm 26, 81
Burns
  incidence/pulmonary complications 217–218
  overview 217
  oxygen delivery methods 33–34
  transportation issues 287
  treatment 218, 218
BURP manoeuvre 60–61
Buscopan (hyoscine butylbromide) 80
Buspirone 348–350

Cabin altitude 294–295
Caffeine, for apnoea in infants/children 299–300
Calcineurin inhibitors, post-transplant immunosuppression 224
CAM-ICU (Confusion Assessment Method for the ICU) 168, 167–168, 169
Cannulae, ECGE 152–153
Capnography 59
Carbapenems 256–257
Carbicarb 156
Carbocisteine 79–80
Carbon dioxide
  balance, arterio-venous 143, 146–147
  children/infants, sensitivity to 299–300
  clearance
    alveolar/pulmonary 14–15, 19, 143–146
    dead space 18, 143–145
    ECGE 152–153
    Heliox 231
    by HFOV 127–131
    by HFV 150
    overview 17–20, 142, 156–157
    by PEEP 145–146
    sodium bicarbonate and 154–156
    tidal volume/frequency 145, 347–351
  overview 142
  production 143, 144, 148
  transport, in blood 146–147, 199
Carbon dioxide narcosis 28, 147
Cardiogenic pulmonary oedema
  CPAP 39–43, 289–290
  hypoxaemia and 23
  NIV study data 49
  NIV *vs.* CPAP 42–43
Cardiovascular system development 298
Catheters
  endotracheal 61–62, 76
  pressure issues 76, 77
  TGI 151, 150–151, 152
  tracheobronchial 76–77
  withdrawal 77
CCV (critical closing volume) 268
Central fatigue 356–358
Cervical spine damage 245, 243–245
Chest drain, insertion technique 254
Chest trauma
  blunt, ventilation strategies 219
  diagnosis 219
  drain insertion technique 254
  pathogenesis 219
Chest wall development 297–298
Cheyne-Stokes breathing 339–340
Children
  airway development, upper 297
  airway obstruction 298, 306
  bronchiolitis 304–305
  cardiovascular system development 298
  chest wall development 297–298
  choanal atresia 300, 302
  congenital diaphragmatic hernia 302–303, 304, 305–306
  consent issues 307–308
  control of breathing 299–300
  CPAP 289–290, 300
  CPAP/NIV 301–302
  dornase alfa 79–80
  head injuries 306
  HFOV 305, 305, 306
  HFV 150
  humidification 307
  hyaline membrane disease 136
  liquid ventilation 228
  lung development in 296–297
  lung mechanics in 300–301
  muscle fatigue in 297–298, 307
  nitric oxide therapy 304
  oxygenation assessment in 118
  permissive hypercapnia 301
  physiology 299, 298–299
  sepsis 307
  ventilation of 301
Chlordiazepoxide 310
Chlorhexidine 261
Choanal atresia 300, 302
Chronic obstructive pulmonary disease (COPD)
  acute necrotizing myopathy 205, 205
  airflow obstruction, pathophysiology 196–198
  in ARF 24
  circulatory collapse 206, 205–206
  clinical presentation 198–199
  high airways resistance, factors affecting 106
  hypercapnia, oxygen-induced 35–36
  management
    aminophylline 201
    CPAP *vs.* NIV 43, 201–202
    cysteinyl leukotriene modifiers 201
    follow-up 207
    glucocorticoids 80
    Heliox 231, 234
    lactic acidosis 200–201
    magnesium sulphate 201
    mechanical ventilation 203, 204, 204, 205
    NIV 49, 201–202, 380–381, 385
    sodium cromoglycate/nedocromil sodium 201
    standard therapy 199–200
  muscle fatigue and 24–25
  NIV issues 46–47
  NIV study data 43–44, 45, 45, 46, 380–381, 385
  pneumothorax 206–207
  therapy targets 384
Ciaglia, Pasquale 322
CIM (critical illness myopathy) 356
CIP (critical illness polyneuropathy) 353–355
Ciprofloxacin 256–257
Circulatory collapse 206, 205–206
Cisatracurium
  overview 174–175
  properties 175
  study data 172–173, 174
  vs. vecuronium 175–176
Clarithromycin 80
Clonidine 278, 279
CMV. *See* Continuous mandatory ventilation (CMV)
Co-operative binding 117
Colistin 81
Combitube 56, 57
Compound unit conventions xiv, xiv
Confusion Assessment Method for the ICU (CAM-ICU) 168, 167–168, 169
Congenital diaphragmatic hernia 302–303, 304, 305–306
Consent issues, infants/children 307–308
Continuous mandatory ventilation (CMV)
  described 104, 108–112
  post-transplant 222–223
Continuous positive airway pressure (CPAP)
  administration 37–38, 39

airway circuit pressure fluctuations 40
in APRV 126–127
bi-level mode 109–110, 111
bronchiolitis 304–305
cardiogenic pulmonary oedema 42–43
children 300, 301–302
circuit/reservoir 40
clinical use 42
COPD 43, 202, 204–205
cuff deflation 71
indications/contraindications 30, 44
interfaces 39
OSAHS 42, 43
overview 37–39, 44
physiological effects 41, 39–41, 42
pneumonia 43–44
post-operative patients 44
in transportation 289–290
trauma 42, 43
Contractility, diaphragmatic 339, 360
Conversion factors, pressure xiv
Cor pulmonale 43
Corticosteroids
AQMS 177
extubation protocol 364, 365, 367
inflammation 81
neuromuscular conduction dysfunction 355
Coughing in secretion clearance 364–367
CPAP. *See* Continuous positive airway pressure (CPAP)
Crafoord, Clarence 393–394
Cricoid pressure application technique 63
Cricothyroidotomy 327–328
Critical care patients
carbon dioxide production in 143
endotracheal intubation 58, 57–58
energy requirements 184–185
over-feeding 185
protein requirements 186
sedation of (*See* Sedation)
tube exchange 83
Critical closing volume (CCV) 268
Critical illness myopathy (CIM) 356
Critical illness polyneuropathy (CIP) 353–355
CTrach LMA 56
Cuff inflators, manual 70
Cuffed tubes 325–326
Cyanide poisoning 120
Cycle time 88
Cycling
expiratory 90–91
inspiratory, described 90
overview 88
Cyclopropane 392
Cyclosporine, post-transplant immunosuppression 224
Cysteinyl leukotriene modifiers, asthma/COPD 201
Cystic fibrosis 79–80, 81
Cytokines 153–154, 265–267, 270
Cytopathic hypoxia 120

Daclizumab 224
Dalziel, John 395–397
Day-time somnolence 43
De-cannulation
airway patency 363, 362–363, 364
airway protection 364, 365
indications 362
protocol 368, 367–368
secretion clearance 366, 364–366, 367
as tracheostomy complication 318–319
Dead space
calculation of 18
elements of 143–145
infants/children 300–301
TGI and 151, 150–151, 152
weaning and 351
Delirium
benzodiazepines 170, 348–350
defined 167
dexmedetomidine 164–165
diagnosis 168, 167–168
haloperidol 170–171
outcomes 169, 349, 348–349, 350
prevention/treatment 169–171
risk factors 168, 168, 169, 349, 348–349, 350
and ventilation weaning 348–350
Dental plaque in VAP transmission 260–261
Deoxyhaemoglobin
in CO_2 transport 199
Depolarizing NMBA agents 174
Depression 349, 348–349, 350
Dexmedetomidine
adverse effects 166
in delirium management 168–169
overview 164–165
properties 163
Dextran 79
Diaphragm
contractility 339, 360
function measurement 27
hernia, congenital 302–303, 304, 305–306
tension-time index 359
Diazepam
primary post-ventilation apnoea 336, 334–336
as sedative 162
Diffuse alveolar haemorrhage
described 137, 137
RM therapy 139
Diffusion
augmented 305–306
coefficient, in oxygenation 132
limitation in low P_{O_2} 14, 10–14, 16
in oxygen transfer 10, 117
oxygenation, distance in 121, 133
Dornase alfa 79–80, 81
Double cannula tubes 326–327
Doxacurium 175
Dräger Oxylog 3000 289, 290, 291
Drinker, Philip 396, 396
Drinker Respirator 396–397
Drugs/venous access 62–63
Duchenne muscular dystrophy (DMD) 377, 379–380
Duty cycles 88–90
Dynamic compliance 8, 7–8, 9
Dynamic hyperinflation 196–198, 206–207

Eaton–Lambert syndrome 355
ECCOR 152
ECGE (extra-corporeal gas exchange) 152–153
ECMO. *See* Extracorporeal membrane oxygenation (ECMO)
Edema. *See* Oedema
EELV. *See* End-expiratory lung volume (EELV)
Electrolyte imbalance disorders 355–358
Electronic cuff pressure controller 70–71
Emphysema 296–297, 318
End-expiratory lung volume (EELV). *See also* Functional residual capacity (FRC)
defined 9
diaphragmatic contractility 339, 360
gas-trapping and 346, 338–346, 347
inspiration effects on 266, 338
Endocrine disorders 355–358
Endotracheal cuff puncture 316–318
Endotracheal intubation
additional channel tubes 66–67, 68
adverse effects/complications 58, 72–73, 240, 239–240, 242, 246
armoured/reinforced tubes 66–67, 69
asthma 49
bronchiolitis 304–305
catheter issues 61–62, 76

Endotracheal intubation (*cont.*)
COPD 44–45
CPAP *vs.*, study data 42–43
critically ill patients 58, 57–58
cuff types 66, 70
defined 54, 55
difficult, incidence data 240
HMEFs 74, 75
indications 58
infants/children 298–299
NIV weaning, study data 47–48
occluded tubes 65
one lung ventilation tubes 66–67
oral *vs.* nasal 63–65
placement, confirmation signs 242
propofol 164
PVC cuffs/tubes 314, 324
re-intubation, post-NIV 48–49
securing, of tube 69, 67–69
size/length issues 65, 65, 66
sub-glottic secretion drainage 72, 71–72, 262
suction arrangement 78
trauma 43
tube cutting technique 66
tube exchange 83
tube resistance, compensation for 114
tube types 64
tubing, monitoring 83–85
Engström, Carl-Gunnar 397, 398
Enteral nutrition
cessation, indications 189
gastric residual volumes 188–189
indications 187
interruptions 189
overview 186
and parenteral 187–188
vs. parenteral 187
pre- *vs.* post-pyloric 188
protocols 188
as therapy 148
Enzyme inhibitors, post-transplant immunosuppression 224
EPAP. *See* Expiratory positive airways pressure (EPAP)
Ephedrine 62–63
Epiglottitis 306
Equipment dead space defined 143–145
Erythromycin 80, 189
Ether 390
Etomidate 62–63, 162, 239, 246
Expiratory cycling
described 89, 90–91
flow-dependent 90–91, 93
pressure support in 106
Expiratory positive airways pressure (EPAP). *See also* Continuous positive airway pressure (CPAP)
airway pressure measurement 38
NIV *vs.* CPAP 198, 202
optimal level issues 47
Expiratory time described 88–90
Explosions, physics of 210
See also Blast injuries
Extracorporeal gas exchange (ECGE) 152–153
Extracorporeal membrane oxygenation (ECMO)
blast injury treatment 217
interventional assist devices 227
post-transplant 226–227
principles 227
Extubation
airway patency 363, 362–363, 364
airway protection 364, 365
CNS pathologies in 351–352
failed 368
indications 362
protocol 364, 365, 367
secretion clearance 366, 364–366, 367
un-planned, as adverse effect 249–250

Face masks
CPAP 39
overview 33–35
oxygen delivery 34, 36, 50
Fastrach™ (intubating) LMA 56
Fatigue. *See* Muscle fatigue
Feeding, practical aspects. *See also* Nutritional support
enteral/parenteral (*See* Enteral nutrition; Parenteral nutrition)
gastric emptying, delayed 189
gastric residual volumes 188–189
interruptions 189
overview 186
protocols 188
route 187
timing 186–187
Fell-O'Dwyer apparatus 392–393
Fenestrations, in tubes 327
Fentanyl
adverse effects 276–280
artificial airway management 62–63
overview 179
properties 179
Ferryl-haemoglobin 211
Fick's Law 120
FiHe (fractional inspired helium concentration) 230, 232–234
Fish oil 190–191
Fleisch pneumotachograph 233–235
Flow-dependent expiratory cycling 90–91, 93
Flumazenil 164, 334–336
Fluoroquinolones 256–257
Foam-filled HVLP cuff 70
Foreign body aspiration, in infants/children 297
Fractional inspired helium concentration (FiHe) 230, 232–234
Fractional inspired oxygen concentration (FiO_2)
aeromedical transportation calculations 294, 294, 295
delivery 33
factors affecting 12–13, 28, 27–28, 29
Heliox 233, 232–233, 234
HFOV settings 127–131
notation xiii
oxygen toxicity and 270, 271
partial pressure of inspired oxygen 132
recruitment manoeuvres 131
France, HMV in 376–377
FRC. *See* Functional residual capacity (FRC)
Frenckner, Paul 393–394
Frog breathing (glossopharyngeal breathing) 374–375
Functional residual capacity (FRC). *See also* End-expiratory lung volume (EELV)
asthma/COPD-related airflow obstruction 197, 196–197, 198
CPAP effects on 39–42
defined 9
diaphragmatic contractility 339, 360
infants/children 300–301
Furosemide 153

Gallbladder, ventilation's effects on 275
Gas exchange
carbon dioxide clearance 17–20
low oxygen partial pressure, causes 12–17
oxygen uptake 9–11
resistance, increased 346–347
Gas-trapping 340, 338–340, 346, 347
Gases
density/viscosity 231
flow patterns 230–232
pressure mechanics 231, 233–235
Gastric regurgitation, reduction of 60–61
Gastroesophageal reflux 274–275
Gentamicin 81, 355
Giertz, K. H. 393–394

Gillick competence 308
Glossopharyngeal breathing (frog breathing) 374–375
Glottic injuries 247–248
Glucocorticoids 80
Glutamine 190
Glyceryl trinitrate, RV failure post-transplant 226
Glycopyrrolate 80, 334–336
Gram-negative organisms, drugs for 81
Granulomas 248
Growth hormone therapy 359–360
Guedel's airways 55, 54–55
Gueugniaud burn treatment 218, 218
Guillain–Barré syndrome 27, 353, 355

Haemoglobin
  carbon dioxide affinity 146–147, 199
  co-operative binding by 10, 117
Haemoglobin oxygen saturation in arterial blood
  dissociation curve 11, 12, 115, 116
  factors affecting 116, 115–116, 117
  notation xiii
  pulse oximetry measurement of 28, 27–28, 29
Haemophilus influenzae 256–257, 306
Haldane effect 146–147
Haloperidol 170–171
Harvey, William 389
Head injuries, in children 306
Heart
  left ventricular failure 43, 273, 339–340
  right ventricular failure 225–226, 272, 274
Heat and moisture exchange filters (HMEF)
  active HMEFs 74
  humidification 74, 75
  overview 74
  random controlled trials 75
  in VAP transmission 75, 262
Heliox
  airway obstruction 232
  application, non-intubated patients 232
  application, ventilated patients 233, 232–233, 234
  application principles 230–232
  asthma management 231, 234
  carbon dioxide clearance 231
  contra-indications 232
  COPD management 231, 234
  cost issues 231–236
  density/viscosity 231
  FiO_2 and 233, 232–233, 234
  future prospects 236
  mode of delivery 232
  overview 230
  respiratory disorder management 232
  respiratory disorders 232
  risks/side effects 234–235
  study data 234
  tumours and 232
  ventilator issues 232, 233, 231–233, 234, 235
Helium 231, 230–231, 232
Heparin 81
HFOV. *See* High frequency oscillatory ventilation (HFOV)
High-frequency oscillatory ventilation (HFOV)
  airway pressure, increasing 122, 123
  ARDS management 127–131, 305–306
  carbon dioxide clearance by 127–131
  children 305, 305, 306
  described 128, 127–128, 129, 131, 149–150
High frequency ventilation (HFV) 149–150
High-volume low-pressure (HVLP) cuff 66, 67, 73, 72–73
History of ventilation
  anaesthesia/pneumothorax 392–394
  anaesthesia/sealed airway 391, 390–391, 392
  benzodiazepines 310
  Blease, John 395, 394–395
  Blease Pulmoflator 394–395
  cuffed tubes 391, 390–391, 392
  Drinker, Philip 396, 396
  Drinker Respirator 396–397
  Fell-O'Dwyer apparatus 392–393
  HMV 376, 374–376, 377
  intensive care medicine ix–x
  iron lungs 373, 372–373, 393, 396–397
  long-term 372–373, 383
  long-term ventilation 372–373, 383
  negative pressure ventilation 372–373, 395–397
  NIPPV 377–379
  NIV 377–379
  orotracheal intubation 391, 390–391, 392
  polio epidemics ix, 32, 372–373, 398, 395–398, 401
  PPV 373, 389, 388–389, 390, 393–394, 401
  prehistory 388–390
  Scandinavia 1949–1952 397–401
  Spiropulsator 394, 393–394
  thoraco-abdominal cuirass 375, 374–375, 396
  timeline 399
  tracheostomy 310, 316, 388
HMV. *See* Home mechanical ventilation (HMV)
Home mechanical ventilation (HMV)
  COPD 380–381, 385
  future issues 385
  history, early 376, 374–376, 377
  OHS 381–382
  organization 381, 384–385
  patient selection 379–382
  PPV 377–379
  quality of life issues 383–384
  therapy targets 384
Hooke, Robert 388–389
Hot water humidifiers 74–75
Humane Societies 389
Humidification
  active HMEFs 74
  aerosol drug delivery 80–82
  artificial airway management 74
  HMEFs 74, 75
  hot water humidifiers 74–75
  infants/children 307
  mucus water content, increasing 79
  overview 74
  VAP transmission 75, 262
Hunter, John 389
HVLP (high-volume low-pressure) cuff 66, 67, 73, 72–73
Hyaline membrane disease 136
Hybrid mode
  described 95–96, 108–112
  suppression 96
  synchronization 97
Hydrocortisone 205
Hydroxydione 310
Hyoscine butylbromide (buscopan) 80
Hyper-metabolism, causes 350, 353–355
Hypercapnia
  aetiology 143
  assessment 22–25, 26
  bronchodilator therapy 149
  carbon dioxide narcosis 28
  chronic, factors affecting 202
  effects of 147, 153–154
  inflammation and 153–154
  iPEEP and 337–340
  management
    Carbicarb 156
    CO_2 production, lowering 148
    ECGE in 152–153
    HFV in 149–150
    overview 147–148, 149
    permissive 150, 153–154

Hypercapnia (*cont.*)
pulmonary therapies, adjunctive 149
sodium bicarbonate 154–156
TGI in 151, 150–151, 152
THAM in 156
ventilation, conventional 148–149
neonates/infants/children 301
over-feeding 185
oxygen-induced 35–36, 199–200
permissive
ARDSnet trials 153, 154, 155
barotrauma and 154
blast injury treatment 216–217
children 301
contra-indications 150
described 153–154
management 150, 153–154
metabolic alkalosis and 153–154
randomized controlled trials 153, 154, 155
reduction of 145
Hypercapnic respiratory failure defined 142
Hyperinflation, static/dynamic 196–198, 206–207
Hypertonic saline 79
Hypertriglyceridaemia 165–166
Hyperventilation therapy, indications for 333
Hypocalcaemia, ionized 147
Hypocapnia
effects of 147
management 147
neonates/infants/children 301
Hypotension 202, 206, 205–206, 239–242
Hypothermia, induced as therapy 148
Hypoventilation issues in low P_{O_2} 13–14, 133
Hypovolaemia 130
Hypoxaemia
assessment 22–25, 115–120
barometric pressure in 132
COPD 47
CPAP 42
mechanisms/management 120–121
nitric oxide as therapy 139
oxygen delivery methods 33–34
PEEP management of 124–125
perfusion and 16–17
post-operative patients 44
prone position as therapy 139
tracheobronchial suctioning 75–76, 77–78
trauma-induced 43
West's zones 18
Hypoxia 239–242, 299–300, 337–340

Hysteresis aetiology 9, 7–9

Ibsen, Bjorn ix, 397–401
Ibuprofen 180
ICAM-1 activation, hypercapnia and 153–154
ICM (intensive care medicine) ix–x
IL-8 activation, hypercapnia and 153–154
Imipenem 256–257
Immune modulating mixes 191
Immuno-suppressed patients 49–50, 253–255
Immunonutrition
arginine 190
glutamine 190
immune modulating mixes 191
insulin therapy, intensive 191–192
omega-3 fatty acids 190–191
overview 189
Immunosuppression, lung transplantation 224, 224
Infants
airway development, upper 297
airway obstruction 298, 306
cardiovascular system development 298
chest wall development 297–298
control of breathing 299–300
CPAP/NIV 301–302
humidification 307
lung development in 296–297
lung mechanics in 300–301
muscle fatigue in 297–298, 307
nitric oxide therapy 304
physiology 299, 298–299
ventilation of 301
Infections
antibiotic-resistant, risk factors 257
control, during transportation 287–288
Heliox and 232
nosocomial, propofol-induced 165–166
respiratory tract isolation 256
stomal, tracheostomy 319
Inflammation
corticosteroids 81
hypercapnia and 153–154
lung injury, ventilator-associated 265–267
Inspiratory cycling described 89, 90, 92
Inspiratory motive force
multiparameter controls 100, 102, 101–102, 103
overview 88, 96–99
pressure as drive 93, 94, 98, 101, 102
volume as drive 91, 94, 98, 99–101

Inspiratory positive airway pressure (IPAP) 202–204
Inspiratory time described 88–90
Insufflation anaesthesia 390–392
Insulin therapy, intensive 191–192
Intensive Care Delirium Screening Checklist 167–168
Intensive care medicine (ICM) ix–x
Intensive care ventilator modes 88–90
Intermittent positive pressure ventilation (IPPV) 289, 314
Intermittent ventilation described 104, 373–374
Intra-pulmonary shunts in low P_{O_2} 14
Intrinsic fatigue 356–358
Intrinsic positive end-expiratory pressure (iPEEP) 39–42, 339, 337–339, 340
Inverse-ratio ventilation (IRV)
applications of 122, 123
inspiratory time prolongation by 125–126
IPAP (inspiratory positive airway pressure) 202–204
iPEEP (intrinsic positive end-expiratory pressure) 339, 337–339, 340
IPPV (intermittent positive pressure ventilation) 289, 314
Ipratropium bromide
asthma/COPD 200
bronchiolitis 304–305
mucus production, decreasing 80
Iron lungs 373, 372–373, 393, 396–397
IRV. *See* Inverse-ratio ventilation (IRV)

Ketamine
asthma/COPD 202
intubation/airway management 240, 246
Ketorolac 180
Kinetic therapy 260
Klebsiella pneumoniae, SDD for 260

Labetolol 348–350
Lactic acidosis 200–201
Lanz inflation balloon 70, 71
Large bowel, ventilation's effects on 275
Laryngeal mask airway (LMA) 56, 57
Larynx
functional anatomy 1
injuries 243, 248, 247–248
swelling, assessment of 363, 362–363, 364
visualizing, in infants/children 297
Lassen, Henry 397–401
Lavoisier, Anton 389
Left ventricular failure 43, 273, 339–340

Length of stay data 332
Leroy technique 390
Lignocaine 81
Linoleic acid 190–191
LIP (lower inflection point) 268, 267–268, 269
Liquid oxygen (LOX) 288
Liquid ventilation 228
Liver, ventilation's effects on 275
LMA (laryngeal mask airway) 56, 57
Long, Crawford 390, 390
Long-term ventilation, history 372–373, 383 *See also* Home mechanical ventilation (HMV)
Lorazepam
  adverse effects 165
  as delirium risk factor 168, 168, 169
  vs. haloperidol 170
  primary post-ventilation apnoea 336, 334–336
  properties 163
  vs. propofol 164
  as sedative, overview 163–164
LoTrach™ tube 259
Lower, Richard 389
Lower inflection point (LIP) 268, 267–268, 269
LOX (liquid oxygen) 288
Lung contusions 219
Lung injury, ventilator-associated
  ARDSnet trials 263–265
  children 301
  lung mechanics role in 267–269, 274
  overview 263–265
  pathophysiology 267, 265–267
  recruitment manoeuvres 268–269
  volume *vs.* pressure 265, 268
Lung transplantation
  airway anastomosis leak/stenosis 223–224
  artificial lungs 227–228
  aspiration 224–225
  challenges 223
  double *vs.* single 225
  ECMO (*See* Extracorporeal membrane oxygenation (ECMO))
  immunosuppression 224, 224
  independent ventilation 225
  interventional assist devices 227
  liquid ventilation 228
  overview 222–223
  pleurodesis 224
  right ventricular failure 225–226
  spontaneous breathing, post-transplant 222–223
Lungs
  artificial 227–228
  blood flow, poorly ventilated 199
  collapsed 136
  compliance 8, 7–8, 9, 42
  development 296–297
  elastance
    abdominal distension in 345, 346
    alveolar recruitment in 346, 345–346
    increased 343
    oedema in 344, 342–344, 345, 346
    pain relief in 345, 346
    pleural disease in 345, 346
    posture in 345, 346
    pulmonary vascular congestion in 344, 342–344, 345, 346
    surfactant in 341–346
  elasticity 4–9
  function, assessment 115–120
  functional anatomy
    airways 3, 1–3, 4
    alveoli/blood supply 3, 4
    gas-trapping in 340, 338–340, 346, 347
  mechanics
    infants/children 300–301
    pulmonary 5, 4–5, 7, 9
  oxygen transfer 10, 9–10, 11
  oxygenation of, surface area in 122, 121–122
  perfusion in low P_{O_2} 16–17, 18
  recruitable forms 268–269
  size issues 298–299
  volumes 9, 27
Lymphoma 232, 363

Macrolides 80
Magill, Ivan 391, 391, 392
Magnesium 355
Magnesium sulphate 201
Management strategy, factors affecting 361
Mandatory breath modes 94, 105, 104–105
Mannitol 79
Matas, Rudolf 392–393
Maxillary sinusitis/middle ear effusions 246–247
Maximal inspiratory pressure measurement 27
MDIs (metered dose inhalers) 83, 84
Mechanical ventilation
  adverse effects/complications (*See* Adverse effects/complications)
  goals of 25
  Heliox (*See* Heliox)
  history (*See* History of ventilation)
  indications (*See* Assessment, of need)
  length of stay data 332
  neuromuscular control of 332
  peak inspiratory pressures 264
Meconium aspiration syndrome 81, 303–304
Mecysteine 79–80
Meltzer, S. J. 393
Metabolic acidosis
  acute renal failure 156
  hypercapnia and 155–156
  sodium bicarbonate for 155
  weaning and 350, 350, 351
Metabolic alkalosis
  permissive hypercapnia and 153–154
  primary post-ventilation apnoea 336
Metaclopramide 189
Metaraminol 62–63
Metered dose inhalers (MDIs) 83, 84
Methohexitone 310
Methylprednisolone, post-transplant immunosuppression 224
Methylxanthines 360
Microcuff™ endotracheal tube 259
Midazolam
  adverse effects 165
  artificial airway management 62–63, 246
  primary post-ventilation apnoea 336, 334–336
  properties 163
  as sedative, overview 163–164
Minute volume dividers 88–90
Mivacurium 355
Mixed venous oxygen saturation
  calculating 119–120
  reduction, in hypoxaemia 133, 134–135
Modes, of ventilation
  adaptive support ventilation® 113, 361
  assist pressure control 108, 109
  assist volume control 108, 109
  automation of 112–113
  Automode® 113
  back-up system 96
  bi-level 111, 109–111, 112
  breath types and 95, 94–95, 96
  expiratory cycling 90–91
  hybrid 96, 95–96, 97, 108–112
  in hypercapnia management 148–149
  inspiratory cycling 90
  inspiratory motive force (*See* Inspiratory motive force)
  mandatory breath 94, 105, 104–105
  multiparameter controls 101–103
  overview 88, 103, 377–379

Modes, of ventilation (*cont.*)
respiratory cycle settings 88–90
SmartCare® 113–114, 361
spontaneous breath (*See also* Continuous positive airway pressure (CPAP))
assist control 109
bi-level 109–110, 111
described 90, 95, 105, 107, 108, 377–379
SIMV 110
tracheostomy 378–379
triggered breath
assist control 109
bi-level 109–110, 111
described 90, 94–95, 105, 107, 106–107, 108, 377–379
hybrid mode 95–96
SIMV 110
tube resistance, compensation for 114
weaning and 361
Monoclonal antibodies, post-transplant immunosuppression 224
Montelukast 201
Morphine
as delirium risk factor 168–169
overview 178–179
properties 179
Morton, William 390
Motor neuron disease (MND) 377, 379–380
Mouth, ventilation's effects on 274–275
MPM model, hyperoxia 270
MRI transfers, intra-hospital 291–293
MRSA 81, 256–257, 260
Mucoactive agents
mucus production, decreasing 80
mucus water content, increasing 79
overview 78–79
polymer cross-linkage reduction 79–80
Mucus production, decreasing 80
Muscle contraction 352, 351–352, 353
Muscle fatigue
as adverse effect 333
assessment of 29–30
asthma/COPD and 24–25
defined 24–25, 357, 356–357, 358
in infants/children 297–298, 307
Muscle mass 359–360
Muscle training 359
Myasthenia gravis 27, 355
Mycophenolate mofetil, post-transplant immunosuppression 224
Myopathy
acute necrotizing 205, 205, 356
acute NMBAs 172–173
AQMS 177
CIM 356
drug-related 355–358
thick filament 356
Myositis 355–358

Naloxone 180, 334–336
Narcotics, monitoring 178
Nasal cannulae 34, 33–34, 35
Nasopharyngeal airways
complications 243–245, 246–247
overview 55, 56
Nasotracheal intubation
bronchiolitis 300, 304–305
complications 315
in VAP transmission 261
Nebulizers
jet 82
mucus water content, increasing 79
overview 82
polymer cross-linkage reduction 79–80
ultrasonic 82
vibrating mesh 82
Nedocromil sodium, asthma/COPD 201
Negative pressure ventilation
described 97
history 372–373, 395–397
HMV 374–377
Neomycin 355
Neonates
airway development, upper 297
cardiovascular system development 298
chest wall development 297–298
congenital diaphragmatic hernia 302–303, 304
CPAP/NIV 301–302
HFOV 305–306
nitric oxide therapy 304
ventilation of 301, 302
Neostigmine 334–336
Neural fatigue 356–358
Neurological disorders 30
Neurological function, ventilation's effects on 276–280
Neuromuscular blocking agents (NMBAs). *See also specific agents*
acute necrotizing myopathy 205
adverse reactions 171, 176–177, 276–280
aminosteroid agents 174, 175–176
AQMS 177
asthma/COPD 203
benzylisoquinolinium agents 174–175
CO_2 production, reduction of 148
in CO_2 production lowering 148
depolarizing agents 174
indications 171, 333
inspiratory time prolongation 125–126
mechanism of action 173–174
monitoring 171–172
non-depolarizing agents 174
overview 172–173, 175
primary post-ventilation apnoea 336, 334–336
study data 172–173
Neuromuscular conduction 335, 355
Neuromuscular disorders, NIV therapy 379–380, 384
Neuromuscular transmission fatigue 356–358
NF-kB activation 153–154, 270
NIPPV. *See* Non-invasive positive pressure ventilation
Nitric oxide
infants/children/neonates 304
RV failure post-transplant 226
as therapy 139
Nitrogen, density/viscosity 231
NIV. *See* Non-invasive ventilation (NIV)
NMBAs. *See* Neuromuscular blocking agents (NMBAs)
Non-invasive positive pressure ventilation (NIPPV) 30, 377–379 *See also* Non-invasive ventilation (NIV)
Non-invasive ventilation (NIV)
ARF 43, 49–50
asthma/COPD 49, 201–202
benefits/limitations 54, 377, 379, 382–384
cardiogenic pulmonary oedema 42–43
children 301–302
contra-indications 201
COPD and 35–36, 43, 46–47
COPD management via 49, 201–202, 380–381, 385
COPD study data 43–44, 45, 45, 46, 380–381, 385
delivery, practical aspects 47, 50–51
history 377–379
NM disease 379–380
OHS 381–382
OSAHS 43
overview 32, 44–45, 51
post-extubation 368
post-transplant 222–223
re-intubation and 48–49
settings, standard 202

study data 44–45
therapy targets 384
in transportation 289–290
weaning 47–48
Non-depolarizing NMBA agents 174
See also specific agents
Nosocomial infection, propofol-induced 165–166
Novalung 152–153, 227
NSAIDs
adverse reactions 181
mucus production, decreasing 80
overview 180
Nuffield, William Richard Morris 396–397
Nutritional support
energy requirements 184–185
enteral (*See* Enteral nutrition)
extubation 367
feeding, practical aspects 186–189
hypocaloric feeding 185–186
immunonutrition 189–191
indications 187
over-feeding 185
overview 184, 192–193
parenteral (*See* Parenteral nutrition)
protein requirements 186
status/outcome 184

Obesity and hypocaloric feeding 185–186
Obesity-hypoventilation syndrome (OHS) 381–382
Obstructive sleep apnoea hypoventilation syndrome (OSAHS) 42, 43
Obstructive sleep apnoea (OSA) 378, 384
Oedema
cardiogenic/non-cardiogenic 23
children 307
in lung elastance 344, 342–344, 345, 346
lung injury, ventilator-associated 265–267
paralysis and 176–177
Oesophagitis 274–275
Oesophagus 243, 274–275
OHS (obesity-hypoventilation syndrome) 381–382
Olanzapine 170–171
Omega-3 fatty acids 190–191
One lung ventilation 66–67
Opioid agonists. *See also specific agents*
adverse reactions 180
as delirium risk factor 168–169
overview 178–180
properties 179
Opioids. *See also specific agents*
adverse effects 276–280
artificial airway management 62–63
gastroesophageal reflux 274–275
primary post-ventilation apnoea 336, 334–336
tidal volumes, poor 336–337
withdrawals 278
Oral hygiene 72
Oropharyngeal airways
cuff deflation 71
defined 54
insertion technique 56
overview 55, 54–55
securing, of tube 69, 67–69
Orotracheal intubation
history 391, 390–391, 392
swallowing dysfunction 247
OSA (obstructive sleep apnoea) 378, 384
OSAHS (obstructive sleep apnoea hypoventilation syndrome) 42, 43
Outlets, for oxygen 58–59, 61, 285–286
Oxy-haemoglobin
in CO_2 transport 199
dissociation curve 12, 16, 147
ECGE 152–153
Oxygen, density/viscosity 231
Oxygen consumption, calculating 119
Oxygen cylinders 62, 288, 293
Oxygen delivery therapy
calculations 119, 292
CPAP *vs.*, study data 42–43
hypercapnia 35–36
interface 34, 33–34, 35, 36
overview 33, 37
PaO_2/ FiO_2 relationship 33
safe use 37, 132–133
target saturations 37
Oxygen toxicity 270, 269–270, 271
Oxygenation
arterial oxygen content, calculating 119
artificial airway management 58–59, 60, 61, 62
diffusion coefficient 132
diffusion distance in 121, 133
ECGE 152–153
HFOV 127–131
HFV management 149–150
hypoxaemia (*See* Hypoxaemia)
inspiratory time prolongation 125–127
low arterial pressure, causes 12–17
mixed venous oxygen saturation, calculating 119–120
nitric oxide as therapy 139
overview 10, 9–10, 11, 115, 116
oxygen consumption, calculating 119
oxygen delivery, calculating 119
patient assessment 118, 115–119, 120
prone position as therapy 139
recruitment manoeuvres 118–119, 131
sigh 132
surface area in 122, 121–122
tracheobronchial suctioning 75–76
$\dot{V}/\dot{Q}$ mismatch 133–139

Paediatric patients. *See* Children; Infants; Neonates; Premature babies
Pain relief in lung elastance 345, 346
Pancuronium 175, 355
Paracetamol 148, 180
Paralysis
adverse reactions 176–177
indications 171
monitoring 171–172
overview 171
Paralytic agents. *See* Neuromuscular blocking agents (NMBAs)
Parapac 289
Parenteral nutrition
vs. enteral 187
enteral and 187–188
indications 187
overview 186
Partial pressure of carbon dioxide in alveolar gas ($PaCO_2$) xiii, 9–11, 17–20
Partial pressure of carbon dioxide in arterial blood ($PaCO_2$)
in COPD/NIV monitoring 46–47
defined 142
factors affecting 17–20, 29–30
inspiratory motive force, pressure-driven 101
inspiratory motive force, volume-driven 99–101
management 148
neonates/infants/children 301
neurological function and 276–280
notation xiii
therapy targets 384
Partial pressure of carbon dioxide (PCO_2) xiii, 299–300
Partial pressure of inspired oxygen 132
Partial pressure of oxygen xiii
Partial pressure of oxygen in alveolar gas (PaO_2) xiii, 10, 9–11, 16, 132

Partial pressure of oxygen in arterial blood (PaO_2)
  aeromedical transportation calculations 294–295
  calculation of 118–119
  changes, surgical patients/PPV/anaesthesia 263
  factors affecting 9–11, 142
  FiO_2 relationship 33
  HFOV settings 127–131
  limitations 118–119
  low partial pressure, causes 12–17
  neonates/infants/children 301
  notation xiii
  optimization issues 47
  oxygen toxicity and 270, 271
Parvolex® 79–80
Pathological shunts in low P_{O_2} 14
Patient–ventilator asynchrony 100
Patient–ventilator dys-synchrony (PVD) 339, 337–339, 340
PAV (proportional assist ventilation) 106–108
PCP pneumonia, drugs for 81
PEEP. *See* Positive end-expiratory pressure (PEEP)
Pendelluft aetiology 9, 7–9
Pentamidine 81
Perfluorocarbons (PFCs), in liquid ventilation 228
Perfusion in low P_{O_2} 16–17, 18
Periodic breathing 299, 299, 300, 340
Permissive hypercapnia. *See also* Hypercapnia
  ARDSnet trials 153, 154, 155
  barotrauma and 154
  blast injury treatment 216–217
  children 301
  contra-indications 150
  described 153–154
  management 150, 153–154
  metabolic alkalosis and 153–154
  random controlled trials 153, 154, 155
Pethidine 168–169, 179
PF ratio 116, 118–119, 270
pH
  alveolar minute volume increase relative to 350, 350, 351
  inspiratory motive force, pressure-driven 101
  inspiratory motive force, volume-driven 99–101
  permissive hypercapnia 153–154
Pharyngo-laryngeal dysfunction 247
Pharynx, functional anatomy 1–4
Phipps Respiratory Unit 375–376
Phosphatidylcholine 6, 4–6, 9
Phrenic nerve damage, breathing capacity and 353–355
Physiological dead space 143–145
Physiological notation
  key xiii
  overview xiii, xiii, xiv
Physiotherapy 149
Piperacillin/tazobactam 256–257
Pleural disease in lung elastance 345, 346
Pneumomediastinum 250–253
Pneumonia
  aspiration 242–243
  assessment 23–24
  children 303–304
  CPAP 43–44
  gastric residual volumes and 188–189
  ventilator-associated (*See* Ventilator-associated pneumonia (VAP))
Pneumonitis, aspiration 242–243, 245
Pneumopericardium 250–253
Pneumothorax
  as adverse reaction 241–242
  anaesthesia and, in history 392–394
  asthma/COPD 202, 206–207
  barotrauma 250–253
  blast injuries 213–214
  chest drain, insertion technique 254
  tension 252, 253
  tracheostomy-associated 318
  trauma-induced 43
  in underdeveloped lungs 296–297
Pneupac series ventilators 289
Poiseuille's law 299
Polio epidemics ix, 32, 372–373, 398, 395–398, 401
Polyethylene glycol toxicity 165
Polymer cross-linkage reduction 79–80
Polyurethane cuffs/tubes 324
Positive end-expiratory pressure (PEEP). *See also* Continuous positive airway pressure (CPAP)
  Aa difference calculation 118
  airway pressure measurement 38
  applications of 124, 125
  bi-level mode 109–110, 111
  bronchiolitis 304–305
  carbon dioxide clearance and 145–146
  complications/contraindications 125, 126, 198
  COPD 204–205
  CPAP, physiological effects 41, 39–41, 42
  future research directions 269
  history 32
  in hypoxaemia management 124–125
  infants/children 300–301
  neurological function and 276–280
  physiological 124
  recruitment manoeuvres 131
  right ventricular failure 225–226
  TGI and 151, 150–151, 152
  tidal volumes, poor 336–337
  tracheobronchial suctioning 75–76, 77–78
  in transportation 289–290
Positive pressure ventilation (PPV)
  history 373, 389, 388–389, 390, 393–394, 401
  HMV 374–377
  mechanism of action 9, 7–9
  PaO_2 changes, surgery/anaesthesia patients 263
  physiological effects 275
  right ventricular performance effects 272, 274
  venous return effects 271–272, 273
Post-surgical patients 44, 164–165
Posture in lung elastance 345, 346
PPHN (pulmonary hypertension of the newborn) 298, 303–304
PPV. *See* Positive pressure ventilation (PPV)
Pranlukast 201
Pregabalin 348–350
Premature babies 301–302
Pressure
  airway, increasing 122, 123
  gases, mechanics 231, 233–235
  lung injury, ventilator-associated 263–265
  lungs, mechanics 5, 4–5, 9–11
Pressure conversion factors xiv
Pressure support ventilation (PSV) 336–337
Primary post-ventilation apnoea 336, 334–336
Procainamide 355
Prone position as therapy 139, 300–301
Propanidid 310
Propofol
  adverse effects 165–166, 276–280
  artificial airway management 62–63
  asthma/COPD 202
  expenditures 279
  overview 164
  properties 163
Proportional assist ventilation (PAV) 106–108
Propylene glycol toxicity 165
ProSeal™ LMA 56
Prostacyclin 81

Pseudomonas aeruginosa, SDD for 260
PSV (pressure support ventilation) 336–337
Psychological morbidity, ventilation's effects on 276–280
Pulmonary hypertension of the newborn (PPHN) 298, 303–304
Pulmonary mechanics overview 5, 4–5, 7, 9
Pulmonary vascular congestion in lung elastance 344, 342–344, 345, 346
Pulmonetic LTV1000 290, 291
Pulse oximetry
  in airway management 59
  need assessment via 28, 27–28, 29
Pulsus paradoxus 199
PVD (patient-ventilator dys-synchrony) 339, 337–339, 340

Quality/length of life principle 22
Quality of life issues 383–384
Quetiapine 170–171
Quinine 355

Rabbit-derived anti-thymocyte globulin (R-ATG) 224
Radiological maxillary sinusitis (RMS) 261
Ramsay scale 161
Rapid shallow breathing index (RSBI) 366
RASS (Richmond Agitation Sedation Scale) 162, 161–162, 336
Rate/tidal volume measurement 26–27
RCT. *See* Randomized controlled trials (RCTs)
Recruitment manoeuvres (RMs)
  as ARDS/ALI therapy 118–119, 131
  described 131
  as diffuse alveolar haemorrhage therapy 139
  future research directions 269
  ventilator-associated lung injury 268–269
Reflectance coefficient 344, 342–344, 345
Remifentanil
  adverse effects 276–280
  expenditures 279
  overview 179–180
  primary post-ventilation apnoea 336, 334–336
  properties 179
Renal function, ventilation's effects on 275–276
Renal replacement therapy (RRT) 350, 350, 351
Reports, semi-quantitative *vs.* quantitative 256
Respiration, periodic 299, 299, 300, 340
Respiratory acidosis
  hypercapnia and 153–154
  sodium bicarbonate for 155, 156
Respiratory alternans 27
Respiratory cycle
  described 89, 88–89, 90
  suppression, adverse effects of 333 (*See also* Muscle fatigue)
  suppression, indications for 333
Respiratory disorders, Heliox management 232
Respiratory quotient 148, 348
Respiratory rate 88
Respiratory rate/tidal volume 145, 341, 347–351
Respiratory syncytial virus (RSV) 81, 304–305
Respiratory system compliance 8, 7–8, 9
Respiratory tamponade 198
Responauts 375–376
Reversibility principle 21–22
Reynolds number (RN) 230–232, 346–347
Rhabdomyolysis 355–358
rhDNase 79–80, 81
Ribavirin 81
Richmond Agitation Sedation Scale (RASS) 162, 161–162, 336
Right ventricular failure 225–226, 272, 274
Risperidone 170–171
RMS (radiological maxillary sinusitis) 261
Rocking beds 374–375
Rocuronium
  neuromuscular conduction dysfunction 355
  overview 176
  properties 175
Rowbotham, Stanley 391, 391, 392
RRT (renal replacement therapy) 350, 350, 351
RSBI (rapid shallow breathing index) 366
RSV (respiratory syncytial virus) 81, 304–305

Salbutamol
  as asthma/COPD therapy 199–200
  bronchiolitis 304–305
  lactic acidosis 200–201
SAPS II model, hyperoxia 270
SARS 50, 81
Saturation of arterial haemoglobin with oxygen (SaO2) 115, 118–119
Sauerbruch, Ferdinand 393
SBT (spontaneous breathing trial) 361, 360–361
Schreiter on recruitment manoeuvres 219
SDD (selective decontamination of the digestive tract) 260
Secretion clearance 366, 364–366, 367
Sedation
  adverse effects 165–166, 245, 276–280
  in CO_2 production lowering 148
  as delirium risk factor 168–169
  management 166–167
  medications overview 163, 162–163 (*See also specific medications*)
  monitoring 161–162
  overview 161, 333
  primary post-ventilation apnoea 336, 334–336
  tidal volumes, poor 336–337
Selective decontamination of the digestive tract (SDD) 260
SensorMedics 3100B 128, 129, 130
Sepsis
  assessment 26, 119–120
  children 307
  and CO_2 production 144, 148
  CPAP, study data 44
  critical illness myopathy 356
  as delirium risk factor 168
  ECMO 226–227
  fish oil 190–191
  insulin therapy, intensive 191–192
  laryngeal injuries 247–248
  nasal intubation 65
  paralytic agents and 173
Severe pulmonary hypertension 150
Shaw, Louis 396, 396
Shock 33–34
Shunting 133–139, 152–153
Shunts in low P_{O_2}
  alveolar/true 14–15
  anatomical 14
  pathological 14
  total, estimation of 12, 16
Sigh described 132
Silicone cuffs/tubes 324–325
Silver cuffs/tubes 325
SIMV. *See* Synchronized intermittent mandatory ventilation (SIMV)
Sleep, ventilation's effects on 276, 277, 278, 279, 349, 348–349, 350, 384
Small intestine, ventilation's effects on 274–275

SmartCare® 113–114, 361
Smith, J. Lorrain 269
Sockets, for oxygen 58–59, 61, 285–286
Sodium bicarbonate 154–156
Sodium cromoglycate, asthma/COPD 201
Sodium nitroprusside, RV failure post-transplant 226
Sorkine study, blast injuries/PIP 216–217
Speaking valves/caps 327
Spencer, Geoffrey 375–376
Spinal fatigue 356–358
Spiropulsator 394, 393–394
Spontaneous awakening study 166–167
Spontaneous breath mode
  assist control 109
  bi-level 109–110, 111
  described 90, 95, 105, 107, 108, 377–379 (*See also* Continuous positive airway pressure (CPAP))
  SIMV 110
Spontaneous breathing, post-transplant 222–223
Spontaneous breathing trial (SBT) 361, 360–361
Staphylococcus aureus 256–257
Starling equation 344, 342–344, 345
Static compliance 8, 7–8, 9
Static hyperinflation 196–198
Steroids, intravenous 200
Steroids, parenteral 205
Stomach, ventilation's effects on 274–275
Streptococcus pneumoniae 256–257
Stridor, post-exubation 363, 362–363, 364
Stroke and oxygen toxicity 270, 271
Sub-glottic secretion drainage 71–72
Succinylcholine 174
Suction apparatus 61–62
Sufentanil 276–280
Supply capacity determinants
  CNS 351–352
  muscle contraction in 352, 351–352, 353
  muscle function, improving 358–360
Supraglottic airways
  Combitube 56
  defined 54
  LMA 56
  nasopharyngeal 55
  oropharyngeal 55, 54–55
Supreme™ LMA 56
Surface area, in oxygenation 122, 121–122
Surface tension, in alveoli 5, 4–5, 9
Surfactant
  in alveoli 6, 4–6, 9
  ARDS/meconium aspiration management 81
  development of 296–297
  dysfunction 267, 265–267
  hyaline membrane disease 136
  in lung elastance 341–346
Suxamethonium 240, 240, 241, 246, 355
Swallowing dysfunction 247, 247, 320–321
Sylvester technique 390
Synchronized intermittent mandatory ventilation (SIMV)
  asthma/COPD 204–205
  described 108–109, 110
  in transportation 289–290
  triggered breaths in 95

T-cell inhibitors, post-transplant immunosuppression 224
Tacroe cuff pressure controller 70–71
Tacrolimus, post-transplant immunosuppression 224
Tension-time index 359
TGI (tracheal gas insufflation) 151, 150–151, 152
THAM (tromethamine) 156
Thick filament myopathy 356
Thiopentone 239
Thoraco-abdominal cuirass 375, 374–375, 396
Thoraco-abdominal motion measurement 27
Tidal volume/frequency in CO_2 clearance 145
Tilting bed/trolley 61
TLC (total lung capacity) 9
Tobramycin 81
TOF (train-of-four) testing 172, 335
Tossach, William 389
Total lung capacity (TLC) 9
Trachea
  functional anatomy 1–3
  injuries 243, 248–249, 318
  stenosis 249, 249, 320
Tracheal gas insufflation (TGI) 151, 150–151, 152
Tracheal intubation 54, 286–287
Tracheal stenosis 249, 249, 320
Tracheo-innominate artery fistula 319–320
Tracheobronchial suctioning
  airway obstruction 78
  catheter issues 76–77
  indications 75
  open *vs.* closed 77–78
  overview 75
  oxygenation 75–76
Tracheostomy
  in airway securement 57–58
  benefits/limitations 377, 382–384
  complications
    airway obstruction 78, 311, 312, 319
    de-cannulation 318–319
    early/late 317, 318–321
    overview 315, 311–315, 316, 317
    perioperative 317, 316–317, 318
    stomal infection 319
    swallowing dysfunction 320–321
    tracheo-innominate artery fistula 319–320
  defined 54
  equipment, bedside 328
  glottic injuries 247–248
  history of 310, 316, 388
  home-use 383
  indications 311, 313
  mini/cricothyroidotomy 327–328
  risk/benefit ratio 314, 311–314, 316
  techniques
    overview 321
    percutaneous 311, 321, 323, 322–323, 324
    single dilator 324
    surgical 322, 321–322
  timing 311–316, 360–361
  tube resistance, compensation for 114
  tubes, choosing 318, 325, 324–325, 326, 327
  VAP transmission via aspiration 258–261
  ventilation modes 378–379
Train-of-four (TOF) testing 172, 335
Tranexamic acid 137
Trans-laryngeal intubation 314, 311–314, 315, 316
Transmural pressure 7, 272
Transplantation, of lungs. *See* Lung transplantation
Transportation issues
  aeromedical 290, 294, 293–294, 295
  equipment/procedures 286, 285–286
  hazards/risks 285, 284–285, 287
  indications/contra-indications 284, 285
  infection control 287–288
  intra-hospital/MRI transfers 291–293
  manual ventilation 290–291
  monitoring 286, 285–286
  need assessment 285
  oxygen supplies 288, 292
  patient preparation 286–287
  tracheostomy 316

transport ventilators 289, 288–289, 290 (*See also specific types by name*)
Trauma
barotrauma (*See* Barotrauma)
cervical spine damage 243–245
chest (*See* Chest trauma)
complications 43
CPAP 42, 43
endotracheal intubation 43
oxygenation via tracheobronchial suctioning 75–76
Triggered breath mode
assist control 109
bi-level 109–110, 111
described 90, 94–95, 105, 107, 106–107, 108, 377–379
in hybrid mode 95–96
SIMV 110
Tromethamine (THAM) 156
True shunts in low P_{O_2} 14–15
Tube cutting technique 66
Tumors, Heliox and 232
Type 1 respiratory failure defined 142
Type 2 respiratory failure defined 142

Uni-Vent Eagle TM754 290, 291
Unit conventions xiv, xiv

Van den Berghe study, insulin therapy 191–192
Vancomycin 81, 256–257
VAP. *See* Ventilator-associated pneumonia (VAP)
Vasodilators, RV failure post-transplant 226
Vecuronium
AQMS 177
neuromuscular conduction dysfunction 355
overview 175–176
properties 175
Venous blood, gas exchange 9–11
Ventilation inequality in low P_{O_2} 15–16, 17
Ventilation/perfusion ($\dot{V}/\dot{Q}$) mismatch
focal alveolar ventilation causes 136
infants/children 300–301
in oxygenation 136, 133–136, 139
prone position as therapy 139
in underdeveloped lungs 296–297
Ventilation requirements, calculation of 17–20
Ventilator-associated lung injury. *See* Lung injury, ventilator-associated
Ventilator-associated pneumonia (VAP)
aetiologies 71–73, 75, 83–85, 253–255
diagnosis 256, 255–256
prevention 72, 75, 258, 257–258
risk factors/outcome 255, 257, 259, 262–263
transmission
via aspiration 257, 258–261
breathing circuit 72, 262
horizontal 261–263
humidification 75, 262
sub-glottic secretion drainage 72, 71–72, 262
treatment 256–257
Ventilator-induced diaphragmatic damage (VIDD)
overview 269, 332, 356
oxygen, safe levels of 270–271
oxygen toxicity 269–270
Ventipac 289
Venturi principle 34, 36
Vesalius, Andreas 388, 389
VIDD. *See* Ventilator-induced diaphragmatic damage (VIDD)
Villar study, PEEP 216
Volume-targeted constant flow mechanical ventilation pressure/time profile 9
Volume-targeted pressure control (VPC) ventilation 104–105, 106
Volumetric CT scanning trial, PEEP 125
VPC (volume-targeted pressure control) ventilation 104–105, 106

Waters system 291, 290–291, 398
Weaning
apnoea
primary post-ventilation 336, 334–336
secondary 340, 339–340
de-cannulation (*See*De-cannulation)
dead space 351
defined 331
extubation (*See* Extubation)
first stage 332–340
gas-trapping 340, 338–340, 346, 347
initiation, timing of 331–332
lung elastance, pulmonary vascular congestion in 344, 342–344, 345, 346
metabolic acidosis 350, 350, 351
metabolic alkalosis 336
muscle training 359
NIV 47–48
patient–ventilator dys-synchrony 339, 337–339, 340
protocols 361–362
second stage 341, 360–361
speaking valves/caps 327
tidal volumes, poor 336–337, 348
time requirements 331
ventilation, neuromuscular control of 332
work of breathing determinants (*See* Work of breathing determinants)
West's zones 16–17, 18, 145, 146
White card test 366
Work of breathing determinants
dead space 351
delirium (*See* Delirium)
diaphragmatic contractility 339, 360
elastance, increased 343, 346
emotional factors 349
FRC/CPAP effects on 39–42
inertia/friction 347, 333–347
metabolic acidosis 350, 350, 351
overview 342
pneumonia 23–24
resistance, increased 346–347
respiratory rate/tidal volume 145, 341, 347–351
supply capacity
CNS 351–352
muscle contraction in 352, 351–352, 353
muscle function, improving 358–360
muscle function disorders 355–358
neuromuscular conduction 335, 355
peripheral neuropathies 350, 354, 353–354, 355

Zafirlukast 201
Ziprasidone 170–171